Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Yesterday, Sept. 10, 2014, 87 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $485.14 to $187,394,342.10.
Highlighted Stocks Traded by Insiders:
Bristol-Myers Squibb Company (BMY) - FREE Research Report Andreotti Lamberto, who is Chief Executive Officer at Bristol-Myers Squibb Company, sold 50,000 shares at $51.05 on Sept. 10, 2014. Following this transaction, the Chief Executive Officer owned 610,809 shares meaning that the stake was reduced by 7.57% with the 50,000-share transaction.
The shares most recently traded at $50.60, down $0.45, or 0.89% since the insider transaction. Historical insider transactions for Bristol-Myers Squibb Company go as follows:
- 4-Week # shares sold: 20,000
- 12-Week # shares sold: 93,723
- 24-Week # shares sold: 93,723
The average volume for Bristol-Myers Squibb Company has been 6.6 million shares per day over the past 30 days. Bristol-Myers Squibb Company has a market cap of $83.7 billion and is part of the health care sector and drugs industry. Shares are down 3.89% year-to-date as of the close of trading on Wednesday.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The stock currently has a dividend yield of 2.85%. The company has a P/E ratio of 31.4. Currently, there are 9 analysts who rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 8 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on BMY - FREE TheStreet Quant Ratings rates Bristol-Myers Squibb Company as a
buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, notable return on equity, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full
Bristol-Myers Squibb Company Ratings Report from
TheStreet Quant Ratings now.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
